Mt Pill

Quick links to important sections

Mt Pill

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mt Pill

Property Description
Active Ingredient Mifepristone
Form Oral Tablet
Pharmacological Class Progesterone Receptor Blocker (Antiprogestin)
General Purpose Manages conditions requiring progesterone signal disruption
Origin Synthetic steroid compound

What Type of Medicine is Mt Pill?

Mt Pill is a prescription-only medicine that utilizes the synthetic steroid compound Mifepristone as its sole active pharmaceutical ingredient. The drug is formally categorized as a Progesterone Receptor Blocker, or an Antiprogestin, based on its core function to oppose the action of the natural hormone progesterone. Mifepristone is a compound that is clinically recognized for its selective and potent antagonistic effects on the progesterone receptor.


What is the Composition and Form of Mt Pill?

The medication is supplied as an oral tablet for administration by mouth, confirming its identity as an oral preparation. This dosage form provides a non-invasive and structured delivery method for the initial phase of treatment. Although provided as a single-agent product, the Mifepristone component is used as the initial step in a sequential two-drug regimen for its general purpose. The composition involves only one active agent, which simplifies the foundational pharmacological action before the necessary second medication is introduced.


What is the General Purpose of a Progesterone Blocker?

The general purpose of this type of medication is to manage or disrupt physiological processes that rely on the presence of progesterone, which is a hormone essential for maintaining certain conditions within the female reproductive system. Mifepristone achieves this through the principle of receptor antagonism, competitively blocking the progesterone docking sites on cells.

What side effects are possible with Mt Pill?

Possible Side Effects and Safety Information

The official safety information for Mt Pill (Mifepristone) is based on documented findings from government regulatory sources, classifying potential effects across various physiological systems. The risk profile distinguishes between frequently occurring, expected reactions and rare, serious adverse events.


Adverse Reaction Classifications

Side effects are officially grouped by the System-Organ Class (SOC) affected, including Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhea), Nervous System Disorders (headache, dizziness), and Reproductive System Disorders (e.g., vaginal bleeding, menstrual disruption).

Reactions categorized as Most Common in regulatory documents often include generalized symptoms such as weakness/fatigue and fever/chills.


Documented Serious Safety Risks

The medication is associated with documented risks of severe adverse reactions, which are highlighted in official warnings. These include the potential for serious bacterial infection or sepsis (which can be fatal and may present without fever) and severe or prolonged heavy vaginal bleeding (sometimes requiring transfusion or intervention). Risks also extend to Adrenal Insufficiency with chronic use and potential cardiac issues like QT Interval Prolongation.


Time-Related and Restrictive Safety Notes

Vaginal bleeding is an expected reaction, with regulatory data noting that it may persist for an average of nine to sixteen days. For long-term use, changes such as endometrial hypertrophy (thickening of the uterine lining) are associated with continued exposure.

Safety restrictions define conditions where Mt Pill must not be used (contraindications), such as confirmed or suspected ectopic pregnancy, chronic adrenal failure, and severe hemorrhagic disorders. Furthermore, use is not recommended in patients with severe hepatic impairment, as explicitly stated in the official safety information.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Mt Pill detail severe, life-threatening complications that require immediate emergency action rather than defining a specific symptom profile for high-dose toxicity. Immediate medical attention must be sought if specific clinical thresholds are met, as these conditions are classified as severe or potentially fatal outcomes.

Official Emergency Action Triggers

Emergency medical care is required when any of the following manifestations occur: Prolonged heavy vaginal bleeding, defined as soaking two thick, full-size sanitary pads per hour for two consecutive hours. Signs of Severe Bacterial Infection or sepsis, including sustained fever (ge 100.4 F or 38 C) lasting more than four hours, severe abdominal pain, or general systemic illness (e.g., weakness, vomiting) persisting beyond 24 hours.

If an individual collapses, has a seizure, or cannot be awakened, contact emergency services immediately. In cases of suspected exposure to a high dose, the Poison Control Center should be contacted for guidance.

Management and Outcome

Regulatory information confirms that no specific antidote is known for Mt Pill overdose. Management, therefore, focuses on symptomatic and supportive treatment to address documented severe outcomes such as fatal septic shock or hypovolemic shock due to hemorrhage. Required supportive measures may include blood transfusions or specific surgical intervention. A follow-up visit is formally required to assess clinical status and monitor for complications.

Therapeutic Uses of Mt Pill

Addressing Hormone-Driven Reproductive and Gynecological Conditions

Mt Pill is primarily used in situations involving certain distressing symptoms that rely heavily on the action of progesterone. It is applied in contexts that involve conditions characterized by periods of heightened symptoms related to early intrauterine pregnancy and early pregnancy loss. It may assist with managing symptoms such as heavy uterine bleeding and pelvic discomfort associated with uterine leiomyomas (fibroids). This provides supportive therapeutic relief against symptoms related to heightened physiological activity.


Controlling Severe Metabolic Disturbances in Cushing's Syndrome

The medication plays a role in managing symptoms related to systemic imbalance in endogenous Cushing's syndrome. It is relevant for easing symptoms associated with persistent hyperglycemia and glucose intolerance in adult patients with endogenous Cushing's syndrome who may also experience Type 2 Diabetes Mellitus. The key benefit may contribute to easing the overall symptom load related to systemic imbalance and helps improve day-to-day comfort during symptomatic periods. It is commonly used in scenarios where additional management of discomfort is required.

Quick Fact: Relief for Systemic Imbalance The medication may assist with stabilizing the challenging symptoms of hyperglycemia and related metabolic stress that arise from specific endocrine conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Mt Pill is approved for use in adult patients for the management of endogenous Cushing's syndrome and for medical termination of intra-uterine pregnancy within specific gestational limits (e.g., up to 70 days as per FDA labeling). Use in the pediatric or geriatric populations is generally not established for Cushing's syndrome treatment.


Populations Who Must Not Use Mt Pill (Contraindications)

Official regulatory documents state that Mt Pill is contraindicated if a patient has any of the following conditions:

  • A confirmed or suspected ectopic pregnancy.
  • Chronic adrenal failure or concurrent long-term corticosteroid therapy.
  • Inherited porphyria or hemorrhagic disorders.
  • An Intrauterine Device (IUD) in place (must be removed prior to use).

Conditions for Restricted or Limited Use

Caution is required, and use may be limited, in patients with specific organ impairments. The maximum dose is limited to 600 mg daily for patients with mild to moderate hepatic impairment or renal impairment when used for Cushing's syndrome; use in severe hepatic impairment is not recommended. Use for controlling hypercortisolism is contraindicated during pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile of Mt Pill (Mifepristone) includes established interactions that may affect the drug's concentration in the body or alter the effects of co-administered substances. These constraints are primarily based on the drug’s metabolism by the CYP3A4 enzyme system.

Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir) can increase Mt Pill concentrations in the bloodstream. Conversely, strong CYP3A4 Inducers (e.g., rifampin, St. John’s Wort) can significantly decrease Mt Pill concentrations.

Interaction Type Interacting Substance/Class Resulting Constraint or Requirement (Official Statement)
Pharmacokinetic (PK) Strong CYP3A4 Inhibitors May increase Mt Pill concentrations; use with caution.
Pharmacokinetic (PK) Strong CYP3A4 Inducers Can lower Mt Pill concentrations.
Pharmacodynamic (PD) Anticoagulant Therapy / Hemorrhagic Disorders Use is constrained due to the risk of heavy bleeding.
Contraindicated Combination Concurrent long-term corticosteroid therapy Must not be used due to potential antagonism of steroid effects.

Additionally, the required co-administered medicine, Misoprostol, must be administered within a specific timeframe—24 to 48 hours—following Mt Pill administration. Mt Pill is also known to increase the concentration of drugs that are substrates for CYP3A4, requiring caution for co-administered medicines that have a narrow therapeutic range.

Mechanism of Action

Molecular Mechanism: Progesterone Receptor Competitive Blockade

The foundational action of Mt Pill is to act as a competitive antagonist on the Progesterone Receptor (PR). This high-affinity molecular binding prevents the natural hormone progesterone from initiating the gene expression necessary to maintain the decidual structure of the uterine lining. This primary mechanism immediately halts the hormonal signaling required to mediate tissue stability, while also causing a secondary blockade of the Glucocorticoid Receptor (GR) at higher concentrations.


Physiological Cascade: Tissue Breakdown and Myometrial Sensitization

The cessation of progesterone-mediated signaling triggers a swift tissue-level cascade involving the reversal of the uterine lining's stability, leading to cellular separation and decidual breakdown. Simultaneously, the drug removes progesterone's inhibitory influence on smooth muscle, causing profound myometrial sensitization. These coordinated physiological changes—tissue instability and muscle responsiveness—are the prerequisites for the subsequent systemic expulsion cascade involving muscle contraction.

Dosage and Administration Information

How to Use Mt Pill

Mt Pill (Mifepristone) is administered exclusively via the oral route as a tablet, and its official usage is structured around two distinct treatment patterns: a fixed-dose sequential regimen and a titrated chronic regimen.

For the sequential regimen, administration begins with a single oral dose of 200 mg on the first day. This initial dose must be followed by a second medication (misoprostol) taken buccally 24 to 48 hours later. A critical procedural constraint is that any existing Intrauterine Device (IUD) must be removed prior to the start of this regimen.


For the chronic, titrated regimen, the medicine is taken once daily, starting at 300 mg. The tablet must be swallowed whole with a meal and should not be crushed or split. Dose adjustments are made in 300 mg increments and are permitted no more frequently than every two to four weeks, up to a maximum daily dose of 1200 mg. The maximum daily dose must not exceed 600 mg in adult patients with renal impairment or mild-to-moderate hepatic impairment, defining a specific population adjustment. In both contexts, the administration of Mt Pill is subject to the operational constraints of a Risk Evaluation and Mitigation Strategy (REMS) program.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mt Pill


Evidence for Management of Early Intrauterine Pregnancy

Mt Pill was studied for its application in research exploring how symptoms change over time related to early intrauterine pregnancy. The main body of research has explored Mt Pill when it is used as the first step in a sequential two-drug regimen. Study designs included short-term Randomized Controlled Trials (RCTs). Research examined specific outcomes such as studies described patterns related to the specific outcome measurement (complete expulsion) of the gestational tissue. Studies also monitored hormone levels, like beta-hCG, over defined time intervals. Findings describe patterns observed in the studies where the sequential regimen was used and tracked outcomes within 1 to 2 weeks following the start of treatment. What remains uncertain is that data on the use of Mt Pill as a monotherapy (used by itself) remain limited.


Evidence for Symptoms Associated with Uterine Leiomyomas (Fibroids)

Mt Pill was studied for its use in research exploring how symptoms change over time for conditions involving periods of heightened symptoms related to uterine fibroids. Research examined a variety of outcomes related to physical discomfort, specifically measuring changes in heavy menstrual bleeding (menorrhagia) and changes in serum hemoglobin levels were also measured. Study designs included intermediate-term RCTs. Findings describe patterns observed in the studies focused on these outcomes across study periods of typically 3 to 6 months. Evidence is limited concerning the durability of the described changes because follow-up durations were limited relative to the chronic nature of the condition.


Evidence for Metabolic Disturbances in Cushing's Syndrome

Mt Pill was studied for its application in research contexts involving fluctuating or unstable symptoms related to the metabolic effects of endogenous Cushing's Syndrome. Research examined specific outcomes related to systemic or functional imbalance, such as persistent hyperglycemia. Study designs included clinical trials and case series. Studies reported how symptoms evolved in the observed populations by measuring changes in HbA1c and fasting glucose levels. Because Cushing's Syndrome is a rare condition, the sample sizes were modest in the studies, and the results apply only to the populations studied with this specific condition. There is limited information for long-term outcomes beyond the typical 6-month trial duration.

Key Studies & References

  1. Mifepristone: MedlinePlus Drug Information
  2. Mifepristone Drug Information: NIH MedlinePlus (Used for Reproductive/Gynecological Indications)
  3. Mifepristone Drug Information: NIH MedlinePlus (Used for Endocrine Indications/Cushing's Syndrome)

Frequently Asked Questions (FAQ)

Common questions about Mt Pill (FAQ)


Q: Does Mt Pill interact with common pain relievers like ibuprofen?

A: Official information indicates that Mt Pill may affect the concentration of certain non-steroidal anti-inflammatory pain medications (NSAIDs), such as ibuprofen, in the bloodstream. Since Mt Pill can increase the levels of these drugs, regulatory sources suggest that the use of these substances may require healthcare supervision or a review of dosage.


Q: Is there a generic version of Mt Pill available?

A: Yes, the active ingredient in Mt Pill, called mifepristone, is available as a generic prescription drug. Like the brand-name version, the use of the generic is subject to specific regulatory safety measures, such as a Risk Evaluation and Mitigation Strategy (REMS).


Q: Is Mt Pill a controlled substance?

A: Mt Pill is a prescription-only medicine. According to U.S. federal regulatory agencies, the active ingredient, mifepristone, is not classified as a federally controlled substance. However, drug classifications can differ, and some other jurisdictions may have different rules.


Q: Have there been any recent safety warnings issued about Mt Pill?

A: Official regulatory agencies, such as the FDA and EMA, are responsible for continuously reviewing safety data for all authorized medicines. These agencies regularly issue updates to the official label or the Risk Evaluation and Mitigation Strategy (REMS) based on their ongoing safety assessments and any new information that arises.


Q: Does Mt Pill require any special monitoring or lab tests?

A: Official regulatory documents confirm that specific monitoring is required when using Mt Pill. For some approved uses, this involves mandatory follow-up to confirm the result of the regimen and to assess the extent of bleeding. Specific lab tests may be necessary depending on the medical condition being managed.


Q: Is Mt Pill known to cause changes in mood or anxiety?

A: Official safety information for Mt Pill does list potential side effects affecting mood. Anxiety is described in regulatory documents as a common or very common adverse reaction in some patient groups. Less common symptoms, like Mental Depression, are also described in regulatory reports.


Q: Is it necessary to take Mt Pill at the exact same time every day?

A: For the chronic treatment regimen, the medicine is prescribed to be taken once daily. While regulatory documents do not mandate a precise time, consistent administration is often noted in guidance for chronic medication use to support stable blood levels.


Q: How long does Mt Pill stay in the body after the last dose?

A: Information from regulatory pharmacokinetics studies indicates that the medication has an extended presence in the body. The terminal elimination time described in official documents indicates a half-life of approximately 18 hours. Detectable levels of the drug may persist for up to 11 days after a single dose.


Q: Can I use alcohol while I am on Mt Pill?

A: For the medical termination regimen, official guidance indicates that alcohol use is generally restricted after taking the first tablet. This restriction is recommended until two days after the completion of the subsequent steps or procedure.


Q: Is Mt Pill known to interact with caffeine?

A: Official product information does not typically identify caffeine as a specific major interaction or contraindication. However, official regulatory guidance emphasizes the importance of disclosing all substances, including medications, vitamins, and herbal products, to the prescribing healthcare professional.

How should Mt Pill be stored and disposed of?

How to Store and Dispose of Mt Pill?

Mt Pill (Mifepristone) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C.

Mandatory Storage Requirements

Requirement Status
Temperature Controlled Room Temperature
Container Store in the container it came in, tightly closed
Protection Protect from excess heat, moisture, and light; do not freeze
Child Safety Keep out of the sight and reach of children

Official Disposal Instructions

Disposal of any unused or expired product must be carried out according to local regulations. Do not discard this medication in household waste or wastewater. Patients are advised to consult their healthcare professional for specific guidance on how to properly discard any no longer needed medicine, ensuring adherence to established protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mt Pill found in:

A-Z Index: